JPMorgan Multi-Asset Growth & Income MATE declare first interim dividend of 1.025p per ordinary share

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) have declared the following distribution:

First interim distribution

A first interim distribution of 1.025 pence per ordinary share, for the year ending 28th February 2022, will be paid on 6th August 2021 to shareholders on the register at the close of business on 2nd July 2021. The ex-dividend date will be 1st July 2021.

For this first interim distribution of the Company’s year ending 28th February 2022, JPMorgan Multi-Asset Growth & Income has elected not to ‘stream’ part of the distribution payment and therefore the whole of the 1.025 pence will be designated as a dividend to shareholders.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn

More articles like this

Analog Devices sees growth accelerating

Analog Devices expects annual revenue growth to average 7% to 10% over the next five years, the chip maker told analysts at a meeting Tuesday morning at the company’s headquarters near Boston. As the name implies, Analog

US FDA approves new Bristol Myers cancer immunotherapy

Bristol Myers Squibb Co said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer. The company

Procter & Gamble-owned Pantene partners with impressive female collective

THE WHAT? Procter & Gamble-owned Pantene has teamed up with ‘impressive, strong, modern, multi-hyphenate women’ to form the new Pantene Conditioner Collective. THE DETAILS Partners of the collective include Chloe Fineman, who features on Saturday Night Live and Dickinson, comedian Meg

Procter & Gamble’s sales jump

Shoppers shrugged off rising prices last year on products like Pampers diapers and Charmin toilet paper, Procter & Gamble said on Wednesday in announcing a jump in its second-quarter earnings. The consumer goods giant reported that

Abbvie looks to crack the cystic fibrosis code

When it comes to cystic fibrosis Vertex is the undisputed heavyweight, but this has not stopped other groups from taking it on. Abbvie is the latest challenger, and data due this quarter could give clues about

Italy to receive 40,000 Merck antiviral drug doses next week

Italy will receive around 40,000 doses of Merck & Co’s (MRK.N) COVID-19 antiviral drug next week, which will add to nearly 12,000 already distributed to hospitals, the special COVID-19 commissioner said on Sunday. “They are intended